{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:23:29Z","timestamp":1775186609410,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Technologies R & D Program Precision Medicine Research","award":["2016YFC0905700"],"award-info":[{"award-number":["2016YFC0905700"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81670061"],"award-info":[{"award-number":["81670061"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0228390","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T18:40:32Z","timestamp":1580409632000},"page":"e0228390","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8381-1823","authenticated-orcid":true,"given":"Chuling","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Ferianc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"issue":"4","key":"pone.0228390.ref001","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"B Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"pone.0228390.ref002","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic Pulmonary Fibrosis","volume":"378","author":"DJ Lederer","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0228390.ref003","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"G Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"pone.0228390.ref004","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/thoraxjnl-2016-208638","article-title":"The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial","volume":"72","author":"LM Dowman","year":"2017","journal-title":"Thorax"},{"issue":"Suppl 1","key":"pone.0228390.ref005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ajt.14562","article-title":"OPTN\/SRTR 2016 Annual Data Report: Lung","volume":"18","author":"M Valapour","year":"2018","journal-title":"Am J Transplant"},{"issue":"2","key":"pone.0228390.ref006","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline","volume":"192","author":"G Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0228390.ref007","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2017.07.062","article-title":"Therapeutic targets in idiopathic pulmonary fibrosis","volume":"131","author":"M Kolb","year":"2017","journal-title":"Respir Med"},{"issue":"120","key":"pone.0228390.ref008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"CJ Schaefer","year":"2011","journal-title":"Eur Respir Rev"},{"issue":"9779","key":"pone.0228390.ref009","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"PW Noble","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"pone.0228390.ref010","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"TE King","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0228390.ref011","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000479976","article-title":"An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)","volume":"94","author":"U Costabel","year":"2017","journal-title":"Respiration"},{"issue":"9","key":"pone.0228390.ref012","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial","volume":"43","author":"D Khanna","year":"2016","journal-title":"J Rheumatol"},{"issue":"3","key":"pone.0228390.ref013","first-page":"235","article-title":"Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease","volume":"31","author":"Y Miura","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"27","key":"pone.0228390.ref014","doi-asserted-by":"crossref","first-page":"e4113","DOI":"10.1097\/MD.0000000000004113","article-title":"A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article","volume":"95","author":"H Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"pone.0228390.ref015","doi-asserted-by":"crossref","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"T Li","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0228390.ref016","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001","volume":"165","author":"S American Thoracic","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"pone.0228390.ref017","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"WD Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"pone.0228390.ref018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCP.0000000000000509","article-title":"Unclassifiable interstitial lung disease: from phenotyping to possible treatments","volume":"24","author":"SA Guler","year":"2018","journal-title":"Curr Opin Pulm Med"},{"issue":"10","key":"pone.0228390.ref019","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/art.30467","article-title":"Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group","volume":"63","author":"D Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"42","key":"pone.0228390.ref020","doi-asserted-by":"crossref","first-page":"e1600","DOI":"10.1097\/MD.0000000000001600","article-title":"Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients","volume":"94","author":"H Huang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"pone.0228390.ref021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1475-2891-12-42","article-title":"The prognostic significance of nutritional status using malnutrition universal screening tool in patients with pulmonary tuberculosis","volume":"12","author":"S Miyata","year":"2013","journal-title":"Nutr J"},{"issue":"6","key":"pone.0228390.ref022","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1164\/ajrccm.160.6.9902115","article-title":"Prognostic value of nutritional status in chronic obstructive pulmonary disease","volume":"160","author":"C Landbo","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"pone.0228390.ref023","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1378\/chest.06-2784","article-title":"Body mass index and mortality in patients with idiopathic pulmonary fibrosis","volume":"131","author":"M Alakhras","year":"2007","journal-title":"Chest"},{"issue":"3","key":"pone.0228390.ref024","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4046\/trd.2012.73.3.162","article-title":"Clinical predictors of survival in idiopathic pulmonary fibrosis","volume":"73","author":"JH Kim","year":"2012","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"6","key":"pone.0228390.ref025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1067\/mpd.2003.152","article-title":"Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis","volume":"142","author":"MW Konstan","year":"2003","journal-title":"J Pediatr"},{"issue":"3","key":"pone.0228390.ref026","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jpeds.2012.08.040","article-title":"Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis","volume":"162","author":"EH Yen","year":"2013","journal-title":"J Pediatr"},{"issue":"3","key":"pone.0228390.ref027","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1183\/09031936.06.00077205","article-title":"Influence of body mass index on the response to asthma controller agents","volume":"27","author":"M Peters-Golden","year":"2006","journal-title":"Eur Respir J"},{"issue":"Suppl 3","key":"pone.0228390.ref028","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1038\/sj.ejcn.1601485","article-title":"The thymus gland is a target in malnutrition","volume":"56","author":"W. Savino","year":"2002","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"pone.0228390.ref029","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12890-018-0575-y","article-title":"Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry","volume":"18","author":"HE Jo","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"4","key":"pone.0228390.ref030","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1378\/chest.128.4.2393","article-title":"Pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"128","author":"HF Nadrous","year":"2005","journal-title":"Chest"},{"issue":"3","key":"pone.0228390.ref031","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/039463201202500314","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress","volume":"25","author":"D Castria","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"pone.0228390.ref032","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1183\/09031936.00115511","article-title":"Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis","volume":"40","author":"EP Judge","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"pone.0228390.ref033","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12931-019-1021-2","article-title":"Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis","volume":"20","author":"U Costabel","year":"2019","journal-title":"Respir Res"},{"issue":"3","key":"pone.0228390.ref034","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000492937","article-title":"Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis","volume":"97","author":"HY Yoon","year":"2019","journal-title":"Respiration"},{"key":"pone.0228390.ref035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.016","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment","volume":"153","author":"SD Nathan","year":"2019","journal-title":"Respir Med"},{"issue":"1","key":"pone.0228390.ref036","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1164\/ajrccm.155.1.9001319","article-title":"Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis","volume":"155","author":"KB Baumgartner","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"pone.0228390.ref037","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1164\/rccm.200612-1759OC","article-title":"Idiopathic pulmonary fibrosis: outcome in relation to smoking status","volume":"177","author":"KM Antoniou","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"pone.0228390.ref038","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3760\/cma.j.issn.0366-6999.20131684","article-title":"Cigarette smoking contributes to idiopathic pulmonary fibrosis associated with emphysema","volume":"127","author":"Q Ye","year":"2014","journal-title":"Chin Med J"},{"issue":"5","key":"pone.0228390.ref039","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.resinv.2015.06.001","article-title":"All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis","volume":"53","author":"T Ogura","year":"2015","journal-title":"Respir Investig"},{"issue":"1","key":"pone.0228390.ref040","doi-asserted-by":"crossref","first-page":"e000105","DOI":"10.1136\/bmjresp-2015-000105","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials","volume":"3","author":"L Lancaster","year":"2016","journal-title":"BMJ Open Respir Res"},{"issue":"6","key":"pone.0228390.ref041","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/resp.13024","article-title":"Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions","volume":"22","author":"JA Galli","year":"2017","journal-title":"Respirology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T21:42:35Z","timestamp":1722375755000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228390"}},"subtitle":[],"editor":[{"given":"Gernot","family":"Zissel","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0228390","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}